New Jersey Institute of Technology

Digital Commons @ NJIT
Theses

Electronic Theses and Dissertations

Fall 1-27-2008

Ultra-fine particle formation using principle of rapid expansion of
supercritical solutions`
Miraj Minesh Sheth
New Jersey Institute of Technology

Follow this and additional works at: https://digitalcommons.njit.edu/theses
Part of the Chemical Engineering Commons, and the Pharmaceutics and Drug Design Commons

Recommended Citation
Sheth, Miraj Minesh, "Ultra-fine particle formation using principle of rapid expansion of supercritical
solutions`" (2008). Theses. 340.
https://digitalcommons.njit.edu/theses/340

This Thesis is brought to you for free and open access by the Electronic Theses and Dissertations at Digital
Commons @ NJIT. It has been accepted for inclusion in Theses by an authorized administrator of Digital Commons
@ NJIT. For more information, please contact digitalcommons@njit.edu.

Copyright Warning & Restrictions
The copyright law of the United States (Title 17, United
States Code) governs the making of photocopies or other
reproductions of copyrighted material.
Under certain conditions specified in the law, libraries and
archives are authorized to furnish a photocopy or other
reproduction. One of these specified conditions is that the
photocopy or reproduction is not to be “used for any
purpose other than private study, scholarship, or research.”
If a, user makes a request for, or later uses, a photocopy or
reproduction for purposes in excess of “fair use” that user
may be liable for copyright infringement,
This institution reserves the right to refuse to accept a
copying order if, in its judgment, fulfillment of the order
would involve violation of copyright law.
Please Note: The author retains the copyright while the
New Jersey Institute of Technology reserves the right to
distribute this thesis or dissertation
Printing note: If you do not wish to print this page, then select
“Pages from: first page # to: last page #” on the print dialog screen

The Van Houten library has removed some of
the personal information and all signatures from
the approval page and biographical sketches of
theses and dissertations in order to protect the
identity of NJIT graduates and faculty.

ABSTRACT
ULTRA-FINE PARTICLE FORMATION USING PRINCIPLE OF
RAPID EXPANSION OF SUPERCRITICAL SOLUTIONS
by
Miraj Minesh Sheth
There are indications in the chemical and pharmaceutical industries that the reduction in

size of a crystalline particle can lead to better performance of the drug compound,
particularly for water insoluble drugs, in the final dosage form. Many particle formation
techniques have been investigated in recent years by researchers to obtain desired
particulate sizes and size distributions. Supercritical fluid technologies have been
successfully investigated for particle formation due to its unique gas/liquid properties in
the supercritical state. In this report, results of particle formation using the principles of
Rapid Expansion of Supercritical Solutions (RESS) have been documented.
In the RESS process, the solution is rapidly expanded through a well-defined
nozzle which leads to formation of ultra-fine particles. An extensive parametric study
was conducted in order to obtain an optimized set of experimental parameters to
formulate ultra-fine particles with narrow particle size distribution. Particles in the nano /
sub-micron range were obtained. Modifications of the RESS process were also explored.
Particles obtained from the RESS process were characterized using tools such as
scanning electron microscopy, light scattering, and, Raman Spectroscopy. This work
illustrates that the RESS processes can be successfully used to produce ultra-fine
particles.
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CHAPTER 1
INTRODUCTION

In 1999, Dr Richard Smalley, Nobel laureate in chemistry, mentioned in US Congress
Testimony [that],
"The impact of nanotechnology on health, wealth, and the standard
of living for people will be at least the equivalent of the combined
influences of microelectronics, medical imaging, computer-aided
engineering, and man-made polymers in this century".'
The field of nanotechnology is growing at a fast rate with a focus on the creation of
functional materials, devices, and systems through the control of matter at the nanometer
scale, and the exploitation of novel phenomena and properties at that length scale. The
rapid development of nanotechnology is equally supported by major scientific and
technological advances in microscopy, material science, molecular-level manipulation,
and scientific understanding at the borderline between classical and quantum physics.'`
Over the past decade, spending on nanotechnology R&D has increased almost
exponentially both in the public and private sector of the industries. In the 2001 fiscal
year, a national nanotechnology initiative was introduced in the United States of
America, making it a top science and technology priority. A 21st century National
Nanotechnology Research and Development Act was signed into law by President
George W. Bush in December 2003 which authorized $3.7 billion to be spent in the 4year period beginning October 2005 on nanotechnology initiatives with an aim to
establish interdisciplinary research centers and accelerate technology transfer into the
private sector. The five participating federal agencies included National Science
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Foundation (NSF), Department of Energy (DOE), NASA, National Institute of Standards
and Technology (NIST), and Environmental Protection Agency (EPA). 3

1.1 Definition of a Nanoparticle
Nanotechnology is the science of creation and utilization of functional materials, devices,
and systems through the control of matter on a nanometer-length scale. A nanometer
(nm) is one billionth (10) of a meter. By definition, any particle with a size smaller than
one micrometer can be referred to as a nanoparticle. However, several national initiatives
are encouraging the development of particles less than 100 nanometers to be referred to
as nanoparticles as they tend to demonstrate some unique physical properties at the
threshold where quantum physics takes over. From a pure physics point of view, when
one dimension of the structure is on the nanometer scale, the structure is referred to as a
quantum well. Moreover, if two sides are of nanometer length, the structure is referred to
as quantum wire, and a quantum dot is used for a structure with all three sides in the
nanometer range. The change in properties arises due to the quantum-mechanical nature
of physics in this small (nano) field. 3 In this report, particles within the size range of 1nm
to 1000nm will be considered as nanoparticles since the question of the precise size range
is still a debate.

1.2 Nanotechnology and Pharmaceuticals
The unique properties of nanoparticles have led to new applications and developments
within the pharmaceutical and medical field. The dosing and efficacy of drug compounds
have improved due to the emergence of nanotechnology. Since the absorption profiles

3
increases, smaller quantities of the drug need to be administered. This in turn reduces the
chances of side effects in the patients. Drug delivery through oral, injective, inhalers,
respirators and, solutions mode have now been made possible at the nanoscale level.
Novel technologies are being developed for targeted drug delivery.
In the pharmaceutical industry, the actives (active pharmaceutical ingredients) in
approximately eighty percent of all medicines are administered in the solid state. In
addition to that, about forty percent of the active pharmaceutical ingredient (API)
currently in the industry pipelines exhibit poor solubility and bioavailability. The
majority of these drug substance falls under biopharmaceutical specification class II
(BSC II) classification. Drugs of class II exhibit high permeability but the rate limiting
step is a function of low solubility, which can be correlated with the dissolution velocity.
Therefore, there is a critical need in the industry to develop formulations with increased
dissolution rates, which can thereby enhance absorption and bioavailability. One of the
ways to achieve this is by reducing the particle size to the nano or sub-micron range.
According to the Noyes-Whitney equation, the poor solubility can be correlated with the
low dissolution velocity.

where, dW/dt is the rate of dissolution, A is the surface area of the solid, C is the
concentration of the solid in the bulk dissolution medium, C, is the concentration of the
solid in the diffusion layer surrounding the solid (saturation solubility), D is the diffusion
coefficient, and L is the diffusion layer thickness. This equation shows that the increase
dissolution velocity is directly proportional to the increase in surface area of the particle.
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This increase in surface area, and thus increase in dissolution velocity can be achieved by
decreasing the particle size of the substance. For instance, the surface area of the particle
would increase by a factor of 10, by micronizing a 50p, m particle to 5μm. There is an
additional increase by a factor of 100 if the same particle is micronized to 500nm.
Furthermore, when the size is below 1 pm, there is additional increase in saturation
solubility (C s ) by a factor of about 2 to 4-6. It is also worth noting that many drug
substances can currently be formulated at a nano-scale level. 4, 5, 6, 7

1.3 Techniques for Particle Formation
Conventional techniques for particle formation, particle size reduction and material
processing used currently in the industries include milling, high pressure homogenization,
spray-drying, freeze-drying and crystallization.

1.3.1 Milling
There are several milling techniques used in the industry. Two of the most common
techniques used in the pharmaceutical industry are discussed below.

1.3.1.1 Ball / Pearl Milling. A ball / pearl mill is one of the oldest means of grinding
materials. The milling is primarily affected by the mill's rotational speed, length of
milling time, quantity of milling medium as well as quantity of the powder. In a ball /
pearl mill, the milling medium (i.e., balls) along with the powder (e.g., drug powder) is
placed in the cylinder and is rotated on a set of rotating wheels. The degree of
comminution, or size reduction, can be increased by increasing the milling time, rotating
the mill at a faster speed, and/or by using a larger ratio of ball weight to powder weight.
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While there are advantages to using these techniques, there are also disadvantages which
can be critical in pharmaceutical industry. Ball / pearl milling can change the
morphology of a solid; a crystalline solid can become amorphous. Moreover, strong
grinding can increase the solid's surface energy and can distort the crystal lattice.
Another critical issue with ball / pearl milling is the erosion from the milling medium
during the milling process. There are also issues of high thermal energy resulting from
the particle-particle and particle-milling medium collisions inside the chamber which can
be critical for thermolabile (heat-sensitive) drug substances. 8

1.3.1.2 Jet Milling. During jet milling, the process material is driven at near sonic
velocity around the perimeter of a chamber by multiple jets of air or steam. Highvelocity collisions particles comprising the powder cause the reduction in size. The
chamber is constructed such that it allows the recirculation of the larger particles which in
turn enhances the effect of this collisions. 9 This type of technique is of limited use to the
production of nano powders. For typical jet milling processes, the final size distributions
are usually within the size range of about 0.1 to 20 μm, and thus contains a very small
fraction (about 10%) in the nanometer range. 4,

6

1.3.2 High Pressure Homogenization
Homogenization is a mechanical process that uses high pressure to break down particles
in the suspension. The suspension is usually passed through a specially designed tiny
homogenizing gap which results in high shear, compression, acceleration, pressure drop
and collision forces acting in this highly turbulent fluid in the gap possessing a high
kinetic energy and eventually causing the breakup of particles and dispersion. The
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pressure required for homogenizing process ranges from 100 to 1500 bar, which can be a
critical issue for temperature and pressure sensitive drug substances. One advantage of
high pressure homogenization over ball / pearl milling is absence of the milling medium.
This technology requires the drug powder to be in the micronized state as well as in
liquid suspension. Researchers have also looked at a combination technique where the
resulting suspension from a precipitation technique is subsequently homogenized in order
to minimize the disadvantages of the crystal growth and stability issues due to
precipitation. 4. 10

1.3.3 Spray Drying
Spray drying is a subsequent technique to a process like homogenization wherein once
the powder is micronized, the water needs to be removed from the suspension to obtain a
stable dry powder. In the spray drying technique, the solution is placed with contact of
hot air in a drying chamber during which the sprays are produced by either rotary or
nozzle atomizers. Dry particles produced due to the evaporation of moisture from the
droplets are then collected in a collection chamber. A schematic example of the
combination technique of homogenization followed by spray drying is shown in Figure
1.1.

7

Figure 1.1 Two-step process of production of drug nano-particles 4 .

1.3.4 Freeze Drying
Freeze drying is also a subsequent step to a process like homogenization. In freeze
drying, the material is allowed to freeze at first and then the material is dried using twostep drying process. In the first drying step (primary drying), the pressure is lowered and
enough heat is supplied to the material so that the water sublimates from solid (ice) to
gaseous phase. The second drying step (secondary drying) is performed to sublimate the
water molecules that are adsorbed during the freezing process. In this step the
temperature is raised even higher and the pressure is often dropped lower (than primary
drying) to break any physico-chemical interactions between the frozen material and water
molecules. This technique is both complex and expensive."

8
L3.5 Liquid Antisolvent (LAS)
The use of liquid antisolvent techniques to crystallize solid compounds has been
prevalent in many industries. This technique has become one of the most promising
particle production techniques in the pharmaceutical industry beecause this technique
eliminates the use of thermal energy which can lead to the degradation of biological
activity of drug particles. In the most common procedures, a poor solvent of a particular
solute is added to the solution in order to precipitate the solute. Water is most commonly
used as an antisolvent for hydrophobic drug compounds, whereas organic solvents are
used for hydrophilic compounds. Precipitation of the solute takes place when the
antisolvent is gradually mixed with solution. The working principle behind this
technique is that during mixing, there is an increase in the molar volume of the solution
that results in decrease in solubility power of the solute and hence the precipitation. Even
though it has been widely used in industry, there is minimal control over the crystal
morphology and size distribution, as well as the presence of residual solvent which is
undesirable. 12

1.4 Motivation
There is a growing interest in pharmaceutical industry to develop efficient drug delivery
system for controlled / sustained release using ultra-fine drug particles. Fine and ultrafine particles possess unique properties that improve dosing (reduced drug dosage),
efficacy of drugs (high therapeutic effect) and bioavailability of the drug. There are
many particle formation processes available in the literature. Although few of these
processes have been used successfully in the pharmaceutical industry for several years,

9

they all hold various drawbacks due to either the application of heat, development of
electrostatic charges and/or residual organic solvents. Also, the processes suffer from
poor control of particle size as well as PSD. In order to overcome this researchers have
started focusing on unconventional techniques to reduce the particle size of the drugs.
Supercritical fluid technologies have shown promising results in order to produce fine
particles with controlled size distribution and morphology.

1.5 Problem Definition

Among the supercritical processes such as Rapid Expansion of Supercritical Solutions,
(RESS), Gas Anti-Solvent (GAS), Supercritical Anti-Solvent (SAS), and Solutionenhanced Dispersion by Supercritical Fluids (SEDS), RESS process have shown
promising results for producing fine particles with narrow size distributions without the
use of any organic solvents. Therefore, RESS process was used in this study as a means
to produce nano / sub-micron particles. Effect of various parameters on precipitation of
drug substance was examined in this study in order to optimize the parameters to obtain
ultra-fine particles.
1.6 Thesis Structure

The first chapter gave a brief introduction on nanotechnology in pharmaceutical industry.
Chapter 2 is a review on particle engineering using supercritical fluid technologies. A
concise background on RESS technique is given in chapter 3. Chapter 4 explains the
experimental setup, nozzle geometries and characterization techniques used during the
study. Discussion of the experimental results is in chapter 5. The scale-up related issues
are discussed in chapter 6 followed by the concluding remarks in chapter 7.

CHAPTER 2
PARTICLE ENGINEERING USING SUPERCRITICAL FLUIDS
TECHNOLOGY — A REVIEW

The thrust to gain an accurate and detailed understanding of supercritical fluids have been
ever increasing since the past two decades. Initial interest in supercritical fluid
technologies was aroused due to the environmental benefits because of the replacement
of organic solvents as well as their unique liquid-like and gas-like properties. Recently,
due to advancement of research it was found that supercritical fluids possess many
unique properties that can improve many chemical processes.

2.1 Definition of Supercritical Fluid
A substance is considered as a supercritical fluid when its thermodynamic state is above
its critical pressure and temperature. At a reduced pressure (P/P c ) ranging from 1.01 to
1.05 and a reduced temperature (T/T c ) from 1.01 to 1.11, a substance is considered a
supercritical fluid. The pressure-temperature phase diagram in Figure 2.1 illustrates the
supercritical region. 14
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Figure 2.1 (a) Pressure-Temperature phase diagram 14 (b) Phase diagram at molecular
level 15 .

Within the supercritical region, a substance's liquid and vapor phases are
indistinguishable starting at their respective critical temperatures (T c ) and pressures (Pa).
In this stage, the supercritical fluid exhibits properties corresponding to both the liquid
and gaseous state, with liquid-like densities, and gas-like flow properties. The density of
supercritical fluids, which is greater than those of gases, allows for more considerable
solvation power. The diffusivity of solutes in supercritical fluids (of the order of 10 -3
cm 2 /sec) is higher than those in liquids (10 -5 cm 2 /sec) due to its lower viscosity (of the
order of 10 -4 g/cm/sec and approximately 100-fold lower than that of liquids) which
results in enhanced mass transfer rates comparable to conventional solvents. An
important property for particle formation is that the supercritical fluids possess gas-like
compressibility properties particularly near the critical point. This results in a very
sensitive solubilizing power; small changes in temperature and/or pressure can tailor its
solvent capacity suited for a particular application. 13,

16
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2.2 Supercritical Carbon Dioxide
All gases can reach a supercritical state if they are thermodynamically above the
specified critical temperature and pressure. However, some gases gain supercritical state
at extremely high temperature and pressures which can be significantly high for
thermolabile (heat-sensitive) solids. Several gases in the supercritical state have been
used for particle formation in industries. Table 2.1 lists several supercritical fluids
studied for research in academia and industry.

Table 2.1 - Critical Constants and Safety Data for Several Supercritical Solvents 4
Supercritical Fluid

Tc (°C)

Pc (bar)

Ethylene
Trifluoromethane
(fluoroform)
Chlorotrifluoromethane
Ethane
Carbon dioxide
Dinitrogen monoxide
(laughing gas)

9.3
25.9

50.3
47.5

28.9
32.3
31.1
36.5

39.2
48.8
73.7
72.6

Sulfur hexafluoride
Chlorodifluoromethane
(HCFC 22; R22)
Propane
Ammonia
Dimethyl ether (wood
ether)
Trichlorofluoromethane
(CFC 11; R 11)
Isopropanol
Cyclohexane
Toluene
Water

45.5
96.4

37.6
49.1

96.8
132.4
126.8

43.0
112.7
52.4

198.0

44.1

235.2
280.3
318.6
374.0

47.6
40.7
41.1
220.5

Safety hazard

Flammable gas

Flammable gas
GRAS
Not combustible but
enhances combustion of
other substances
Combustible under
specific conditions
Extremely flammable
Flammable and toxic
Extremely flammable

Highly flammable
Highly flammable
Highly flammable

The selection of the supercritical fluid is largely based on the physicochemical
properties of the compound of interest and also the chemical process. For pharmaceutical
applications, the most commonly used supercritical fluid is carbon dioxide because of its
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low critical temperature (T c = 31.1 °C) and reasonable critical pressure (P c = 73.7 bar).
Supercritical carbon dioxide is nontoxic, nonflammable, has GRAS (`generally
recognized as safe') status, and is relatively inexpensive. It also doesn't react strongly
with many organic solvents and can be recycled at the end of a process.

2.3 Supercritical Fluid Techniques for Particle Formation
The need for unconventional particle formation techniques has been given a great deal of
attention in the chemical and pharmaceutical industries due to ever growing interest in
nanotechnology as well as the search for more environmentally friendly technologies.
The increase in interest for small particles with a narrow particle size distribution can be
explained due to a need for most sophisticated drug delivery systems and the effect of
particle size on the solubility, dissolution rate, targetability, and bioavailability of drug
compounds. Furthermore, the appropriate aerodynamic size, shape, and apparent density
are prime requirements to ensure the best drug delivery to the lung. The use of
supercritical fluids for particle formation applications has gained a lot of momentum in
past decade. Figure 2.2 summarizes several supercritical fluid technologies researched
till date for particle formation.

Figure 2.2 Schematic of supercritical fluid technology processes for particle formation.28
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2.3.1 Gas Anti-Solvent (GAS) Process
In this batch precipitation process, a compound with low solubility is dissolved in an
organic solvent before a miscible gas is added as an anti-solvent. This process requires
steady addition of a supercritical fluid into a liquid organic solution containing the
particular solute (drug) and is dependent on the ability of the liquids to solubilize a large
amount of gases. As the supercritical fluid significantly expands, the volume of the
organic solvent reduces its density and the dissolved drug precipitates. The precipitation
is caused by the volumetric expansion of the organic solution which is accompanied by a
sudden drop of liquid solvent strength. The GAS process possesses several advantages
over other conventional and unconventional particle formation techniques, but also
includes some drawbacks. There are chances of residual traces of organic solvent in the
final product which can lead to a serious limitation in pharmaceutical industry. A
broader particle size distribution can result due to variable supersaturation ratios caused
by the gradual increase of supercritical fluid volume. An additional drying phase is
required after GAS process since the particles are mainly produced in the liquid phase.
The process scale-up can be a challenge since the conditions of the pressure are
transient. 1 6

2.3.2 Supercritical Anti-Solvent (SAS) Process
In this process, the supercritical fluid is substituted as the liquid anti-solvent which causes
the precipitation of the solute dissolved in the primary solvent. The process is carried out
at the specific temperature and pressure conditions at which the primary liquid solvent
and supercritical anti-solvent are completely miscible. A rapid supersaturation of solute
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dissolved in the liquid results due to the diffusion of supercritical fluid into the liquid
solvent. This, in turn, results in the precipitation of micronized particles. This process
differs from the GAS process in that the precipitation during the SAS process occurs in a
supercritical fluid-rich phase. However, like the GAS process, it is difficult to obtain
particles with a narrow particle size distribution. The complexity arises due the formation
of droplets as well as mass transfer into and out of the droplets. In order to produce
smaller particles, the mixing or mass transfer of the solvent and anti-solvent (supercritical
fluid) needs to be faster than the SAS process. 4 , 17

2.3.3 Solution-enhanced Dispersion by Supercritical Fluids (SEDS)
The SEDS process works on a similar principle as that of SAS, in which the supercritical
fluid and the organic solution are introduced concurrently in the reactor, and the added
anti-solvent leads to the precipitation of the solid. However, in the SEDS process, a
coaxial nozzle is used in which the liquid solution is introduced in the inner channel
while the supercritical fluid flows in the outer tube. The premixing of the two channels
before the injection point allows the dispersion of the organic solution and supercritical
fluid and allows for better mass transfer. This process has been successful to produce
fine particles. However, one of the drawbacks of this process is the difficulty to produce
particles without any trace of solvent. 17

2.3.4 Rapid Expansion of Supercritical Solution (RESS)
The RESS process is one of the very few supercritical technologies which do not involve
the use of an organic solvent. This process relies on the solvent properties of the
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supercritical fluid. This process has been successfully used to produce fine particles with
a narrow particle size distribution. When the supercritical solution is rapidly expanded
through the nozzle, the pressure and temperature drops suddenly based on JouleThompson expansion phenomenon. This leads to high supersaturation, and nucleation
and growth of the ultra fine particles with narrow size distribution.

2.4 Remarks
The RESS process for particle engineering has been explored in this study for the
following reasons. First and foremost, the RESS process does not involve the use of any
organic solvent. This provides an utmost advantage in pharmaceutical industry where
any trace of organic solvent in the drug compound is undesirable. Another significant
advantage is that RESS process has a capability to precipitate ultra fine particles (nano /
sub-micron range) with narrow size distribution. Additional advantages of RESS process
are discussed in the subsequent chapters.

CHAPTER 3
RAPID EXPANSION OF SUPERCRITICAL SOLUTIONS — A REVIEW

3.1 History
Rapid Expansion of Supercritical Solutions technology has been investigated by
researchers for about a century. In 1879, Hannay and Hogarth first described the process
using a basic concept of RESS as,
"When the solid is precipitated by suddenly reducing pressure, it is
crystalline, and maybe brought down as a 'snow' in the gas, or on the
glass as a frost,... ,,17, 18
However, this technology has not been really focused on as a phenomenon to
produce particles with desired size and size distribution until about the early 1980s. In
1983, the first of the many patents related to RESS process was approved which
demonstrated processes and apparatus for formulating fine powders of solid materials.
Results were found using polymers and silica systems. 18 Since then, the rapid expansion
of supercritical solutions technology has been investigated by many researchers around
the world as a means to formulate particles with desired particle size and narrow particle
size distribution. Lately, many more researchers have been exploring this process to
produce fine particles for pharmaceutical drug substances. The utmost benefit of RESS
process is that it is free of any organic solvent and hence, the solvent wastes can be
greatly reduced. This process has been successfully used to fabricate particles in nano /
sub-micron particle size range with controlled size distribution. Also, the operating
conditions, particularly the temperature, are reasonably mild. Thus, this process is very
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attractive to the pharmaceutical industry, since there is minimal thermal degradation of
the thermolabile drug (API) substances."'
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3.2 Definition of RESS
When a supercritical solution, comprised of a solute (usually drug or polymer) is
dissolved in supercritical solvent, is expanded through a specially designed nozzle, the
characteristic speed of the expansion in the nozzle is approximately on the same order of
magnitude as the speed of sound. Due to the rapid nature of this process, it is referred to
as Rapid Expansion of Supercritical Solution. The process follows the principle of JouleThomson expansion (isenthalpic expansion) wherein the sudden pressure drop at constant
enthalpy, leads to a drop in temperature resulting in very high supersaturation. The high
supersaturation of solute causes high nucleation rates and hence reduces the growth of
fine particles as shown in Figure 3.1.
Nucleation dominant over
particle growth

Figure 3.1 Qualitative supersaturation profiles corresponding to a precipitation process 19
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A graphic representation of expansion phenomenon (Figure 3.2) has been well
demonstrated in the papers of Dr. Ram Gupta and his group at Auburn University. 20 The
next section (Section 3.3) describes the process in greater detail.

Figure 3.2 Schematic of RESS process 20 .

3.3 Process Description
Figure 3.3 schematically presents four steps involved in the RESS process.

Figure 3.3 Schematic Flow diagram of RESS process 21 .

3.3.1 Rapid Expansion of Supercritical Solution (RESS)
The first step in the RESS process is the dissolution of a solute (drug/API) in supercritical
fluid (SCF). A solvent, at conditions higher than T c and P C , is pumped from the cylinder
to an extraction chamber. The dissolution properties of the solute depend on the
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extraction conditions (temperature and pressure) as well as the chemical characteristics
which includes polarity of the solute. Therefore, it is essential to estimate the solute
solubility in the supercritical solution. The challenge arises especially for pharmaceutical
compounds due to the lack of availability of the data for the specific drug compounds in
the literature. The solubility of the solute in supercritical solution can be determined
experimentally or calculated by modeling solid-fluid equilibria using the equation of state
(EOS) approach. The extraction conditions are determined based on the solubility
results. The goal is to attain equilibrium concentration of solute in SCF at a given
pressure and temperature (usually referred to as Pext and Text) and mean residence time.
This can be achieved easily by small changes in pressure and/or temperature. It is also
essential to ensure the equilibrium conditions in order to obtain a high yield of the
particles. `
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3.3.2 Rapid Expansion of a Supercritical Solution into a Liquid Solvent (RESOLV)
The RESOLV process is a slight modification of the conventional RESS process in that
the supercritical solution is expanded into the liquid solvent instead of ambient air. The
rationale behind this modification is to inhibit the particle growth in the expansion jet that
is found in RESS process. The liquid solvent used as an expansion medium is usually deionized water; however, other liquids in which the solute is insoluble can also be
explored. There is a potential challenge particle agglomeration in the suspension may
arise which can be prevented by addition of a stabilizing agent.

21 ' 22
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3.3.3 Rapid Expansion of Supercritical Solutions with Solid Cosolvent (RESS-SC)
Generally, high molecular weight solids have low solubility in supercritical carbon
dioxide (SC-CO2) as CO, is non-polar. The introduction of a solid cosolvent into a RESS
process can enhance the solute (drug) solubility to some extent as well as prevent the
growth by reducing the intra-particle interactions. The cosolvent in this case is solid at
nozzle exit conditions. The growth by coagulation is inhibited due to the presence of
excess solid co-solvent in the expansion chamber. Figure 3.4 schematically represents
this phenomenon. The choice of solid cosolvent depends on its solubility in supercritical
fluid, its vapor pressure (which should be high), non-reactivity with drug or supercritical
fluid, and the cost. The solid cosolvent can be removed later by using techniques such as
freeze-drying or sublimation. Menthol is one of the solid compounds that satisfies the
above requirements and also is an acceptable additive in food and pharmaceutical
industry. 4, 20

Figure 3.4 — Schematic of RESS-SC process 4 , 19

CHAPTER 4
EXPERIMENTAL SECTION

4.1 Materials
Fenofibrate (C201 121 C104, 99%, pure), and Ibuprofen (C131 1180,, .98%, pure), were
-

-

purchased from Sigma Aldrich. Tween 80 (from non-animal source) was purchased from
Sigma Aldrich. All these chemicals were used without any further purification. Carbon
dioxide (high purity SCF grade) was purchased from Welco Gas Products. Water was
deionized and purified using Milli-Q® Ultrapure Water Purification Systems.

4.2 RESS Apparatus
The RESS experimental setup at can be seen in Figure 4.1. The setup allows it to be used
for the modifications of RESS processes (i.e., RESOLV and RESS-SC).

Figure 4.1 Schematic of RESS apparatus at New Jersey Institute of Technology.
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The setup consists of a high pressure pump for pressure generation and pressure
maintenance during the rapid expansion process. The check valve is followed by a
heating coil. The T-junction allows the supercritical fluid to travel to a cosolvent
chamber if RESS-SC process is performed which is controlled by the valves. The
pressure gauge monitors the operating pressure maintained in the setup. The rupture disc
rated at 7000psi is installed in the supercritical fluid pump and right before the extraction
chamber as a safety precaution. The dissolution of the solute (drug/API) in SC-CO2 takes
place in the extraction chamber. The chamber is followed by a valve attached to the
nozzle for depressurization. The nozzle can be attached to the expansion chamber
containing aqueous liquid (deionized water) in order to run experiments for RESOLV
process.

4.3 Nozzle Geometry
The two distinct nozzle geometries (Nozzle 1 and Nozzle 2) used to examine their effect
on the particulate size, particle size distribution (PSD) and morphology are shown in the
Figure 4.2.
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Figure 4.2 Schematic of nozzle geometries.

4.4 Characterization
Characterization of the particles produced using the RESS processes was performed
using scanning electron microscopy (SEM), light scattering (LS) and raman
spectroscopy.

4.4.1 Scanning Electron Microscopy (SEM)
SEM (LEO 1520 VP FESEM) was used to perform a qualitative analysis of the particles
obtained from the RESS processes. The particle size and morphology were analyzed.
For the analysis, the particles were collected on the carbon tape located on the top of
aluminum stubs. For the analysis of the sample from aqueous liquid suspension (0.1%
v/v tween 80 / DI-water), the solution was first sonicated for approximated 20 minutes
and few droplets were added on the SEM stub. The stub was then placed under vacuum
in dessicator to ensure the sample was dry before analysis. SEM micrographs from
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different regions of the stubs were captured. Image processing and analysis software
(ImageJ by NIH) was used to perform particle size analysis. This was done in order to
obtain a particle size distribution for the particles directly collected on the SEM stub.
Multiple images for each experiment were processed in order to get a statistically valid
representation of the particles. Image analysis results were compared with light
scattering (where available) results and were found to be significantly similar.

4.4.2 Light Scattering
Light scattering (Beckman Coulter LS 230) was used to measure the hydrodynamic
diameter of aqueous solution of drug and deionized water. Polarization Intensity
Differential Scattering (PIDS) was also performed using the Fraunhofer diffraction
model. For the RESS process, after the collection of particles, deionized water was
added along with approximately 0.1% of Tween 80 and sonicated for twenty minutes
before performing the analysis. One of the challenges faced for light scattering was that
the solution was very dilute for some experiments. Image processing was performed for
these experiments.

4.4.3 Raman Spectroscopy
Raman spectroscopy (Mesophotonics SE1000) was used to compare the physical
characteristics of drug substances before and after processing. The instrument is
equipped with 785nm (N-IR) laser beam. The laser power is —300mW. Raman gives
the fingerprint of the molecule and the peaks represent the bonding interactions of the
molecules.
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CHAPTER 5
RESULTS AND DISCUSSION

An extensive parametric study has been conducted to explore the effect of parameters on
size, PSD, and morphology of the particles precipitated by Rapid Expansion of
Supercritical Solutions and its modifications. The effect of nozzle geometry (nozzle 1
and nozzle 2), extraction pressure (100 — 200bar), initial solute amount (100 — 300mg),
and heated nozzle temperature (20 — 60°C), for RESS process has been studied. Light
scattering and scanning electron microscopy were used to characterize the crystals. Table
5.1 presents the details of the experiments, process conditions, and particle size and
morphology of precipitated powders.
The RESOLV process has also been examined in this study. The effect of
extraction pressure (100 — 250bar) on particle size, size distribution and morphology has
been investigated while maintaining all other parameters constant. The results obtained
from the study are discussed in this chapter.

12
13
14
15

1
2
3
4
5
6
7
8
9
10
11

Exp.

100
150
200
250

60
60
60
60

100
100
100
100

Extraction Conditions
Pressure
T (°C)
Drug
(bar)
Amount
(mg)
100
100
60
100
60
100
60
100
100
100
60
100
100
60
100
150
60
100
100
200
60
100
60
200
100
300
60
100
100
60
100
100
60

ambient
ambient
ambient
ambient

ambient
ambient
ambient
ambient
ambient
ambient
ambient
ambient
ambient
ambient
ambient

Pressure
(bar)

ambient
ambient
ambient
ambient

1
1
1
1

7
7
7
7

Expansion Conditions
Nozzle Nozzle Nozzle
Length
Type
T (°C)
(inches)
7
ambient
1
3
ambient
1
3
1
ambient
3
60
1
2
3/4
60
3/4
60
2
3/4
60
2
3/4
60
2
3/4
60
2
3/4
2
40
3/4
ambient
2

Table 5.1 - Tabulated Experimental Results

762.0
762.0
762.0
762.0

Nozzle
Diameter
(p.m)
762.0
762.0
508.0
762.0
609.6
609.6
609.6
609.6
609.6
609.6
609.6

RESOLV
RESOLV
RESOLV
RESOLV

RESS
RESS
RESS
RESS
RESS
RE SS
RE SS
RESS
RESS
RESS
RESS

Process

Yes
Yes
Yes
Yes

N/A
N/A
N/A
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

LS

3.451
13.749
7.923
14.676

Average
Particle
Size (pm)
2.385
0.766
4.112
1.232
0.289
5.521
4.977
2.169
5.302
1.826
8.466

1.12 - 8.09
0.71 - 56.54
0.61 - 23.35
2.66 - 124.5

0.50 - 11.35
0.24 - 5.39
1.66 - 13.78
0.415 - 7.85
0.06 - 3.57
1.25 - 23.99
3.13 - 25.52
0.25 - 10.89
0.86 - 24.15
0.69 - 14.18
1.68 -32.11

Results
Range
(μm)

quasi-cubicle
quasi-cubicle
rod-like
quasi-cubicle
quasi-cubicle
quasi-cubicle
quasi-cubicle
quasi-cubicle
quasi-cubicle
quasi-cubicle
quasi-cubicle,
rod-like,
needleshaped
quasi-cubicle
quasi-cubicle
quasi-cubicle
quasi-cubicle

Morphology
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5.1 Effect of Nozzle Geometry

The effect of nozzle geometry has been examined using Fenofibrate as a solute for the
RESS process. The effect of nozzle length (L = 7 inches and L = 3 inches) has been
studied.

Figure 5.1 SEM micrographs and cumulative PSD for particles precipitated by RESS (a)

exp 1 (b) exp 2.

30
The particles in these set of experiments (exp. 1 & 2) have been directly collected
on the SEM stub with carbon tape attached to it. The inner diameter (ID) of the nozzle
was constant for both the lengths at 762μm. As seen in Figure 5.1, approximately 50% of
the particles collected using a nozzle with length, L = 3 inches were below 0.550 gm,
whereas for the nozzle with length, L = 7 inches about 50% were below 2.5 pm. Also,
the mean size of particles decreases from 2.385 pm to 0.766 gm with a decrease in nozzle
length from 7 inches to 3 inches as shown in Figure 5.1. The increase in particle size and
PSD can be attributed to the extra particle growth due to the increase in their residence
time in the longer nozzle.
The next set of experiments (exp. 2 and 3) has been conducted in order to
examine the effect of nozzle diameter. For these experiments, the nozzle length was
constant at 3 inches while two nozzle diameters D = 508 pm and D = 762 pm have been
used. Fenofibrate is used as a solute and all other parameters are kept constant. Figure
5.2 shows the results obtained from the experiment. It can be seen that with the increase
in nozzle diameter from 508 gm to 762 p.m for nozzle 1 the particle size decreases from
4.112 gm to 0.766 pm. It is observed that for nozzle with diameter D = 508 gm, the
morphology of precipitated particles is rod-like shape while for D = 762 pm , it is quasicubicle. At this point, there is no reasonable explanation for the change in morphology.
The experiment for nozzle diameter D 508 pm has been repeated to eliminate a
possibility for error; however, similar morphology was obtained. The results contradict
the findings of Huang et al who reports that a change in nozzle diameter had no
significant change in the morphology or size of precipitated aspirin. 24 It was also shown
in the literature that there was no significant effect of nozzle diameter on morphology or
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morphology or particle size of naphthalene when precipitated using RESS.
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Domingo et

al performed RESS process on several organic compounds in which they reported needlelike morphology for benzoic acid crystals, salicylic acid crystals and aspirin crystals
using a capillary and a frit nozzle. 26

Figure 5.2 SEM micrographs and cumulative PSD for particles precipitated by RESS (a)

exp 2 (b) exp 3.
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The effect of two distinct nozzle geometries (as shown in Figure 4.2) on particle
size, PSD and morphology has also been explored (exp. 4 & 5). The rationale behind
designing a new nozzle (Nozzle 2) was that the sudden decrease in the capillary diameter
results in very high velocity. This leads to almost zero difference in the residence time
for the particle growth to occur in the nozzle. This would minimize the time for the
particle growth in the capillary which may lead to small particle size with narrow
distribution.

Figure 5.3 SEM micrographs and cumulative PSD for particles precipitated by RESS (a)
exp 4 (b) exp 5.
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For these experiments the particles (Fenofibrate) were collected in an empty flask.
The nozzle was heated at 60 °C during expansion. After the expansion, 0.1% aqueous
solution of Tween 80 in deionized water was added and was sonicated for 20 minutes.
The particles deposited on the sides of the flask were scrapped off using a spatula. It is
evident from the SEM micrographs that some particles were agglomerated after the
addition of deionized water due to the hydrophobic nature of the solid. This resulted in a
slightly broader particle size distribution. The results of image processing were
comparable to that of light scattering. From the cumulative plot in Figure 5.3, it can be
seen that —50% of crystal precipitated from nozzle 2 are below 0.170 gm; while for
nozzle 1, 50% of the crystals are below 1 gm. The average size of the particles
precipitated from nozzle 1 is 1.232 gm while that from nozzle 2 is 0.289 gm. Moreover,
the size distribution of crystals obtained using nozzle 2 was much narrower than those
precipitated from nozzle 1. For these reason, nozzle 2 was used for all the remaining
parametric study in this report.

5.2 Effect of Extraction Pressure
The effect of extraction pressure (exp. 5, 6 & 7) has been explored for the RESS process
while keeping all the remaining parameters constant. The pressures examined were 100,
150 and 200 bars for Fenofibrate as a solute.
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Figure 5.4 Effect of extraction pressure on fenofibrate precipitation. SEM micrographs
of fenofibrate particles precipitated (a) exp 5 (b) exp 6 (c) exp 7.

An increase in extraction pressure resulted in the increase in the particle size of
fenofibrate drug substance. The particle size distribution was also found to be widened
with an increase in pressure. Figure 5.4 shows the SEM micrographs and the cumulative
distribution at 100bar, 150bar, and 200bar. The average particle size at 100bar was found
to be 0.289 pm, which increases to 5.521 μm at 150bar and 4.977 μm at 200bar. Similar
trend was also obtained using ibuprofen as the drug solute. The results obtained from
these experiments were in the similar lines of the previous literatures. Huang et al. 24
and, Hirunsit et al. 25 have shown in their respective research that as the extraction
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research that as the extraction pressure (Pex t) increases at constant temperature (T ex t), the
solubility of the drug substance also increases, i.e. the initial solute concentration
increases. The higher initial solute concentration results in higher supersaturations upon
expansion which leads to higher nucleation. The nucleation rate is inversely proportional
to the particle volume. Finer particles are obtained as Pext increases due to higher
supersaturation and subsequent higher nucleation rates. Nucleation is followed by
growth process which in turn leads to wider particle size distribution.

5.3 Effect of Extraction Temperature
It is been reported that lower extraction temperature results in early nucleation along the
nozzle leading to larger particle size. Domingo et al. 26 have reported similar results for
aspirin, benzoic acid, and phenanthrene. However, contrasting results have been reported
by Mohamed et al. 27 saying there is no effect on particle size with variations in extraction
temperature when the solute concentration is kept high. Hirunsit et al. 25 also reports that
for Ibuprofen at different extraction temperature, very high velocity and very close initial
nucleation leads to almost zero difference in the residence time for the particle growth to
occur in the nozzle. Therefore, there is minimal effect on the particle size of Ibuprofen.
In this study the extraction temperature was kept constant for all the experiments.
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5.4 Effect of Initial Solute Concentration in SCF
The effect of initial solute concentration has also been examined in this study. The initial
amount of drug placed in the extractor has been varied as 100mg, 200mg and 300mg.

Figure 5.5 Effect of initial solute concentration in SCF on Fenofibrate precipitation.
SEM micrographs of fenofibrate particles precipitated (a) exp 5 (b) exp 8 (c) exp 9.
It is reported that initial solute amount in the extractor plays a part in particle
formation process using RESS. 27 It was found that increase in initial fenofibrate
concentration results in increase in particle size as well as the size distribution (exp. 5, 8
& 9). Figure 5.5 shows the results at 100mg, 200mg and 300mg solid concentration. The
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average particle size for 100mg drug amount was found to be 0.289

which increases

to 2.169 ?AM for 200mg and 5.302 1.4111 for 300mg. Decrease in the initial amount of solid
placed in the extractor decrease in the amount of the fenofibrate dissolved in SC-CO2.
This reduces supersaturation, lowers nucleation rates and makes less fenofibrate available
for growth and lower particle size is obtained. However, it is dependent on other
extraction conditions. Similar observations were reported by Ginosar et al. where they
observed smaller particles are produced at lower solute concentration. They found that at
higher solute concentration of phenanthrene in RESS resulted in bimodal distribution of
primary nanoparticles and larger micron-sized aggregates. 27 At lower final solute
concentration, the supersaturation and nucleation rate are lower which may prevent the
growth of the particles resulting in smaller particles.

5.5 Effect of Heated Nozzle Temperature

Effect of heated nozzle temperature on the particle size, size distribution and morphology
has been examined(exp. 5, 10. & 11). Nozzle was heated using the heating tape
controlled by the Dimerstat. The thermocouple was attached to the nozzle to monitor the
temperature of the nozzle.
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Figure 5.6 Effect of heated nozzle temperature on Fenofibrate precipitation. SEM

micrographs of fenofibrate particles precipitated (a) exp 5 (b) exp 10 (c) exp 11.

Heating of nozzle during expansion resulted in significant change in particle size,
distribution and the morphology of the precipitated particles of fenofibrate. When the
nozzle was kept at the ambient temperature (-20 °C), mixed morphology of the crystals
was observed. SEM micrograph in Figure 5.6(c) shows the existence of combination of
needle-shape, rod-like and cubical crystals. The crystal size of the particles and the size
distribution was also significantly larger as compared with the crystals precipitated when
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the nozzle temperature was maintained at 40 °C as well as 60 °C. Approximately 50% of
crystals were smaller than 0.170 p.m and 1.40 p.m for 60 °C and 40 °C respectively,
whereas for ambient temperature 50% particles were smaller than 8.5 pm. The average
particle size was found to be 0.289 pm at 60 °C nozzle temperature, which increases to
1.826 p.m at 40 °C and 8.466 pm at ambient conditions. An increase in nozzle
temperature increases the solid solubility in SC-CO2 which increases the supersaturation
and at the same time growth is also restricted. This reduces the particle size by inhibiting
the particle growth as less solute is available for particle growth.

5.6 RESOLV
Experiments were conducted on RESOLV process (exp. 12-15) in order to compare its
results with conventional RESS process. It is reported by Y. P. Sun's group that
expansion of the supercritical solution in aqueous solution inhibits the growth of particles
after nucleation. This result in formation of crystals in nano and/or sub-micron range
suspended in aqueous solution. 21 ' 22 In this study, the effect of extraction pressure on the
particle size, size distribution and morphology of the particles were examined at 100,
150, 200 and 250 bars. Figure 5.8, 5.9, 5,10, and 5.11 corresponds to the SEM
micrographs of experiments at the respective extraction pressures. The micrographs
show that the particles tend to agglomerate in the RESOLV process. This is due to
hydrophobic nature of the solute, fenofibrate. Because of the hydrophobic nature, these
particles tend to form agglomeration in order to reduce the interactions with water
molecules. There was a distinct trend seen from the image analysis and light scattering
results. As the extraction pressure increased the agglomerate size and the size
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results. As the extraction pressure increased the agglomerate size and the size
distribution increased. Figure 5.7 confirms that as the extraction pressure increased from
100bar to 150bar, the agglomeration increased and so did the agglomerate size
distribution. There was no distinct change as pressure was increased from 150bar to
200bar, however, at 250bar; there was again an increase in agglomeration size and size
distribution. The pattern is confirmed by the SEM micrographs. The micrographs show
that the individual particle size is in nano / sub-micron range for extraction pressure of
100bar and increases is the extraction pressure increases. It is evident from the Figure
5.11(b) that at extraction pressure of 250bar, there were particles below 2μm size,
however; it is impossible to obtain a representative individual particle size as they are
agglomerated. Y.P. Sun and group have reported that the introduction of stabilizers such
as surfactants, or polymers has shown to reduce the amount of agglomeration and obtain
particles in nano / sub-micron range. 22 Future work is planned to investigate addition of
stabilizers in the aqueous liquid to avoid agglomeration.

Effect of Extraction Pressure on RESOLV

Figure 5.7 Cumulative frequency of the agglomerate size distribution at respective
extraction pressures.

Figure 5.8 SEM micrographs for precipitated fenofibrate particles using RESOLV process at

P er t

l00bar.

Figure 5.9 SEM micrographs for precipitated fenofibrate particles using RESOLV process at Pert = 150bar.

Figure 5.10 SEM micrographs for precipitated fenofibrate particles using RESOLV process at Pex t = 200bar.

Figure 5.11 SEM micrographs for precipitated fenofibrate particles using RESOLV process at P ext = 250bar.

45
5.7 Raman Analysis
The crystallinity of the drug substance affects its bioavailability, physical and chemical
stability. The chances of the crystalline nature of the drug to be affected using the RESS
process are reasonable due to the influence of high pressure and temperature. In this
study, Raman spectroscopy was performed on unprocessed and processed drug substance.

Figure 5.12 Raman spectra plots for fenofibrate (a) unprocessed (b) processed.

46

Figure 5.12 shows the comparisons of Raman spectra for the (a) unprocessed and
(b) processed fenofibrate. From the spectra it can be seen that there is a slight chance that
the starting material may be in amorphous phase, which disappeared after processing for
Fenofibrate. The level of crystallinity of the processed drug would be important factor to
be analyzed. It is previously reported that the precipitated drug substance retains its
crystalline structure after RESS processing. 20 Further work is planned to perform the
analysis at New Jersey Institute of Technology.

CHAPTER 6
SCALE-UP OF RESS PROCESS

Scale-up of supercritical fluid technologies is a challenging issue in the industry.
However, large commercial high-pressure extraction plants are already employed in the
food industry for decaffeination of coffee beans that are compliant with the current good
manufacturing practice (cGMP) standards administered by food and drug administration
(FDA). Therefore, scaling up the supercritical technology for pharmaceutical industry
would not require anything novel.20
Even though promising results are being obtained on the laboratory scale,
commercial implementation of these processes is a rarity at this stage. Two of the most
important factors influencing the scale-up implementation of these processes are safety
and economical issues. The high pressure equipments of supercritical processes cost
much higher than those for the conventional processes. In the pharmaceutical industry,
the formulation of fine particles does not require scale-up on a very large scale. For
example, Palakodaty et al. in their chapter, "Pharmaceutical and Biological Materials
Processing with Supercritical Fluids", reports that annual requirements for salbutamol
sulfate, an antiasthmatic drug, in United States is in the region of 500-1000 kg. This
substantially reduces the capital costs associated with high pressure equipments. 20, 28
The experiments in this study were conducted at the laboratory scale. 0.10g drug
substance gave the best results with corresponding process parameters. For processing
0.10g of drug (fenofibrate) in one batch at P ext = 100bar and T ex t = 60 °C, approximately
7.2g of SC-CO 2 was consumed for extraction. Rough calculation for straight scale-up of
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RESS to process 500g of drug (fenofibrate) in one batch at the above conditions shows
that the extraction chamber will have to be of 60L capacity which will consume
approximately —36kg (60L) of SC-CO 2 . There is also a possibility to perform RESS as a
semi-continuous or continuous process. Multiple extraction vessels can be arranged in a
sequence for a semi-continuous process. This allows other vessels to run in an
uninterrupted extraction while one vessel is loading or unloading. The examples of
designs for a commercial extraction process used in soil industry were shown in Alonso
E., et a1 31 . The extractor volume for these designs ranged from 90L, 163L, and 244L
with carbon dioxide flow rates of 452, 538 and, 1138 kg/h-1 respectively. Up to four
extraction chambers were used simultaneously in order to run the process in semicontinuous fashion. Therefore, by using a 90L vessel for RESS process, up to 750g of
drug can be processed using one batch process (i.e., —195 kg/year). The total processing
can increase for semi-continuous batch process where more than one batch can be
processed per day.
The operating temperatures for RESS process are generally lower as compared to
several other conventional pharmaceutical operations. This eliminates the possibility of
burn-related risks associated with the processes. The inclusion of pressure-relief
mechanisms, pressure rupture discs on supercritical fluid pump, and high pressure vessels
provides protection against over pressurizing the mechanical components of the system.
In RESS process like any other supercritical technologies, the process takes place in the
closed system. Therefore, the entire process equipment does not need to be in a
controlled environment. The equipment including the high pressure pump and carbon
dioxide recycling system can be outside the clean room in the explosion proof room.
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Only the particle collection equipment (expansion chamber) is required to be in the
controlled environment to prevent contamination of the drug substance. RESS process
does not utilize any other solvent apart from carbon dioxide, which is GRAS acclaimed.
This prevents the exposure risk of the personnel working on the process. Moreover,
absence of any other solvent allows the fluid (usually carbon dioxide) to be recycled and
a cost-effective measure. Most high pressure equipments are manufactured using 316L
stainless steel, which are least durable for long-term due to its corrosion proof nature and
can be cleaned easily using organic solvents. 20, 28, 29
Thus, the RESS process can be scaled-up and adapted to the cGMP compliance in
a straightforward manner with major difficulty for the low-volume pharmaceutical fine
particle formation. A successful scale-up of RESS will depend on the proper
understanding of the thermodynamics of nucleation and coagulation process as well as
the relationship between the process parameters and the physical and chemical
characteristics of resulting particles.

CHAPTER 7
CONCLUSIONS

This study has engaged the use of rapid expansion of supercritical solutions (RESS)
process for formation of fine particles. The effect of nozzle length, diameter and
geometry, extraction pressure, initial solute concentration, and heated nozzle temperature
were studied for RESS process. The effect of extraction pressure was explored for
RESOLV process. It was found that all of the above factors had an effect on particle size
and size distribution. It was also found that the lower nozzle diameter (D = 508 gm),
length (L= 3inches), and ambient nozzle temperature resulted in the rod-like morphology
different from the other nozzle geometries. The extraction pressure

(Peat

= 100bar),

extraction temperature (T ex t = 60 °C), initial solute concentration (100mg), and nozzle
temperature (T N = 60 °C) using nozzle 2, gave nano / sub-micron particles and a narrow
size distribution. The average particle size was found to be 0.289 gm. Particle size and
the size distribution increases with an increase in extraction pressure, initial solute
concentration, nozzle length, as well as decrease in nozzle temperature. The study
confirms that claims that RESS process can be used to formulate very fine particles, with
a controlled size distribution, and most importantly for pharmaceutical industry, it is a
solvent free technique.
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